The University of Pennsylvania has sued BioNTech, alleging that the German biotechnology company has underpaid royalties owed to Penn for patents used in BioNTech’s and Pfizer’s COVID-19 vaccine. The ...

We came across a bullish thesis on BioNTech SE on Memyselfandi007’s Substack. In this article, we will summarize the bulls’ thesis on BNTX. BioNTech SE's share was trading at $103.80 as of March 4th.

Aug 6 (Reuters) - The University of Pennsylvania has sued German biotechnology firm BioNTech (22UAy.DE), opens new tab in Pennsylvania federal court, accusing the company of underpaying royalties for ...

Add Yahoo as a preferred source to see more of our stories on Google. The logo of BioNTech is pictured at Biontech's research laboratory for individualised vaccines against cancer in Mainz, Germany, ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the vaccine technology continue to play out on several other fronts. Pfizer and ...

BioNTech SE's $11.1bn BMS deal for BNT-327 highlights promise in PD-L1/VEGF oncology, but clinical validation is still needed. Despite strong COVID vaccine cash flow, BioNTech's share price stagnates ...

Mainz, Germany, March 10, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced plans for an independent company to be established and led by BioNTech ...

BioNTech reported surprisingly strong sales of its COVID-19 vaccine in the third quarter, which reached €1.24 billion ($1.35 billion) and more than doubled the consensus estimate of $652 million. It ...

Acquisition aims to strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next milestone in the execution of its ...